Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone

D. Lebovic, James E Hoffman, B. M. Levine, H. Hassoun, H. Landau, Y. Goldsmith, M. S. Maurer, R. M. Steingart, A. D. Cohen, R. L. Comenzo

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

The treatment of systemic light-chain (AL) amyloidosis with symptomatic cardiac involvement at diagnosis remains a challenge. We report the results of 40 consecutive newly diagnosed AL cardiac patients who were not candidates for stem cell transplant and therefore received monthly oral melphalan and dexamethasone. Median survival was 10.5 months and baseline predictors of survival included gender, troponin I and interventricular septal thickness. The most significant predictor of survival was response to therapy. The haematological response rate was 58% (23/40) with 13% (5/40) complete responses; most responses were noted in <3 cycles. Achievement of a rapid response to therapy extends survival.

Original languageEnglish (US)
Pages (from-to)369-373
Number of pages5
JournalBritish Journal of Haematology
Volume143
Issue number3
DOIs
StatePublished - Nov 2008
Externally publishedYes

Fingerprint

Melphalan
Stem Cell Transplantation
Amyloidosis
Dexamethasone
Light
Survival
Troponin I
Stem Cells
Therapeutics
Transplants

Keywords

  • Amyloidosis
  • Immunoglobulin light chains
  • Melphalan

ASJC Scopus subject areas

  • Hematology

Cite this

Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. / Lebovic, D.; Hoffman, James E; Levine, B. M.; Hassoun, H.; Landau, H.; Goldsmith, Y.; Maurer, M. S.; Steingart, R. M.; Cohen, A. D.; Comenzo, R. L.

In: British Journal of Haematology, Vol. 143, No. 3, 11.2008, p. 369-373.

Research output: Contribution to journalArticle

Lebovic, D. ; Hoffman, James E ; Levine, B. M. ; Hassoun, H. ; Landau, H. ; Goldsmith, Y. ; Maurer, M. S. ; Steingart, R. M. ; Cohen, A. D. ; Comenzo, R. L. / Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. In: British Journal of Haematology. 2008 ; Vol. 143, No. 3. pp. 369-373.
@article{11a4861b39be4b3c8a78c0591bb99052,
title = "Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone",
abstract = "The treatment of systemic light-chain (AL) amyloidosis with symptomatic cardiac involvement at diagnosis remains a challenge. We report the results of 40 consecutive newly diagnosed AL cardiac patients who were not candidates for stem cell transplant and therefore received monthly oral melphalan and dexamethasone. Median survival was 10.5 months and baseline predictors of survival included gender, troponin I and interventricular septal thickness. The most significant predictor of survival was response to therapy. The haematological response rate was 58{\%} (23/40) with 13{\%} (5/40) complete responses; most responses were noted in <3 cycles. Achievement of a rapid response to therapy extends survival.",
keywords = "Amyloidosis, Immunoglobulin light chains, Melphalan",
author = "D. Lebovic and Hoffman, {James E} and Levine, {B. M.} and H. Hassoun and H. Landau and Y. Goldsmith and Maurer, {M. S.} and Steingart, {R. M.} and Cohen, {A. D.} and Comenzo, {R. L.}",
year = "2008",
month = "11",
doi = "10.1111/j.1365-2141.2008.07327.x",
language = "English (US)",
volume = "143",
pages = "369--373",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone

AU - Lebovic, D.

AU - Hoffman, James E

AU - Levine, B. M.

AU - Hassoun, H.

AU - Landau, H.

AU - Goldsmith, Y.

AU - Maurer, M. S.

AU - Steingart, R. M.

AU - Cohen, A. D.

AU - Comenzo, R. L.

PY - 2008/11

Y1 - 2008/11

N2 - The treatment of systemic light-chain (AL) amyloidosis with symptomatic cardiac involvement at diagnosis remains a challenge. We report the results of 40 consecutive newly diagnosed AL cardiac patients who were not candidates for stem cell transplant and therefore received monthly oral melphalan and dexamethasone. Median survival was 10.5 months and baseline predictors of survival included gender, troponin I and interventricular septal thickness. The most significant predictor of survival was response to therapy. The haematological response rate was 58% (23/40) with 13% (5/40) complete responses; most responses were noted in <3 cycles. Achievement of a rapid response to therapy extends survival.

AB - The treatment of systemic light-chain (AL) amyloidosis with symptomatic cardiac involvement at diagnosis remains a challenge. We report the results of 40 consecutive newly diagnosed AL cardiac patients who were not candidates for stem cell transplant and therefore received monthly oral melphalan and dexamethasone. Median survival was 10.5 months and baseline predictors of survival included gender, troponin I and interventricular septal thickness. The most significant predictor of survival was response to therapy. The haematological response rate was 58% (23/40) with 13% (5/40) complete responses; most responses were noted in <3 cycles. Achievement of a rapid response to therapy extends survival.

KW - Amyloidosis

KW - Immunoglobulin light chains

KW - Melphalan

UR - http://www.scopus.com/inward/record.url?scp=54049148697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049148697&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2008.07327.x

DO - 10.1111/j.1365-2141.2008.07327.x

M3 - Article

C2 - 18691169

AN - SCOPUS:54049148697

VL - 143

SP - 369

EP - 373

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -